TNFRSF9 and neoplasm: Using 4-1BB agonists as immunomodulatory payloads in anticancer vaccines or in tumor targeting virus vectors are especially promising approaches to exploit the potential of 4-1BB co-stimulation to enhance anti-tumor immunity while avoiding deleterious effects associated with the systemic introduction of 4-1BB signals.